Month: February 2016

Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Women’s Sexual Health Annual Meeting

CRANBURY, N.J., Feb. 26, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that data on a bremelanotide and alcohol use interaction Phase 1 study were presented today in a Research Podium Session …

Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Women’s Sexual Health Annual Meeting Read More »

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on February 16, 2016

palatin_reconnectlogo_id_0351eca35bc5_ CRANBURY, N.J., Feb. 16, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2015.  Recent Highlights Bremelanotide development for Female Sexual Dysfunction (FSD): …

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on February 16, 2016 Read More »

Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2016 Results

CRANBURY, N.J., Feb. 10, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2016 operating results on Tuesday, February 16, 2016 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February …

Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2016 Results Read More »

Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction

CRANBURY, N.J., Feb. 8, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application …

Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction Read More »

Palatin Technologies To Present At The BIO CEO & Investor Conference

CRANBURY, N.J., Feb. 4, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 18th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 18th Annual BIO CEO & Investor Conference will take place February 8-9 at the Waldorf Astoria in New York …

Palatin Technologies To Present At The BIO CEO & Investor Conference Read More »

Scroll to Top